Empagliflozin and the risk of Gout: Analysis from the EMPagliflozin compaRative effectIveness and SafEty (EMPRISE) study

被引：0
|
作者：
Koeneman, Lisette [1 ]
Tesfaye, Helen [2 ]
Paik, Julie M. [2 ]
Zabotka, Luke E. [2 ]
Htoo, Phyo T. [2 ]
Schmedt, Niklas [3 ]
Seman, Leo [4 ,5 ]
Wexler, Deborah J. [6 ,7 ]
Patorno, Elisabetta [2 ]
机构：
[1] Lilly Deutschland GmbH, Global Med Affairs, Bad Homburg, Germany
[2] Harvard Med Sch, Dept Med, Brigham & Womens Hosp, Div Pharmacoepidemiol, Boston, MA 02115 USA
[3] Boehringer Ingelheim Int GmbH, Dept Global Epidemio, Ingelheim, Germany
[4] Boehringer Ingelheim Pharmaceut Inc, Ridgefield, CT USA
[5] Clin Dev & Med Affairs, Ridgefield, CT USA
[6] Harvard Med Sch, Massachusetts Gen Hosp, Dept Med, Boston, MA 02115 USA
[7] MGH Diabet Ctr, Div Endocrinol, Boston, MA USA
来源：
INNERE MEDIZIN | 2024年 / 65卷
关键词：
D O I：
暂无
中图分类号：
R5 [内科学];
学科分类号：
1002 ; 100201 ;
摘要：
P21-02
引用
收藏
页码：S145 / S145
页数：1
相关论文
共 50 条
  • [21] Empagliflozin selected cardiovascular and safety outcomes in routine care: First results from the EMPagliflozin compaRative effectIveness and SafEty (EMPRISE) study
    Patorno, E.
    Pawar, A.
    Franklin, J. M.
    Najafzadeh, M.
    Deruaz-Luyet, A.
    Brodovicz, K. G.
    Sambevski, S.
    Bessette, L. G.
    Kulldorff, M.
    Schneeweiss, S.
    METABOLISM-CLINICAL AND EXPERIMENTAL, 2020, 104
  • [22] Empagliflozin Selected Cardiovascular and Safety Outcomes in Routine Care: First Results from the Empagliflozin Comparative Effectiveness and Safety (EMPRISE) Study
    Patorno, Elisabetta
    Pawar, Ajinkya
    Franklin, Jessica
    Najafzadeh, Mehdi
    Deruaz-Luyet, Anouk
    Brodovicz, Kimberly
    Sambevski, Steven
    Bessette, Lily G.
    Kulldorff, Martin
    Schneeweiss, Sebastian
    DIABETES, 2019, 68
  • [23] The EMPagliflozin compaRative effectIveness and SafEty (EMPRISE) study programme: Design and exposure accrual for an evaluation of empagliflozin in routine clinical care
    Patorno, Elisabetta
    Najafzadeh, Mehdi
    Pawar, Ajinkya
    Franklin, Jessica M.
    Deruaz-Luyet, Anouk
    Brodovicz, Kimberly G.
    Santiago Ortiz, Adrian J.
    Bessette, Lily G.
    Kulldorff, Martin
    Schneeweiss, Sebastian
    ENDOCRINOLOGY DIABETES & METABOLISM, 2020, 3 (01)
  • [24] Reduced healthcare utilization in routine care initiators of empagliflozin with and without heart failure: interim analysis from the EMPagliflozin compaRative effectIveness and SafEty (EMPRISE) study
    Pawar, A.
    Patorno, E.
    Deruaz-Luyet, A.
    Brodovicz, K.
    Ustyugova, A.
    Gautam, N.
    Ortiz, A. Santiago
    Schneeweiss, S.
    Najafzadeh, M.
    EUROPEAN HEART JOURNAL, 2019, 40 : 3063 - 3063
  • [25] Health-Care Costs and Medication Burden in Routine Care Initiators of Empagliflozin: A First Analysis from the Empagliflozin Comparative Effectiveness and Safety (EMPRISE) Study
    Pawar, Ajinkya
    Patorno, Elisabetta
    Deruaz-Luyet, Anouk
    Brodovicz, Kimberly
    Ustyugova, Anastasia V.
    Gautam, Nileesa
    Bessette, Lily G.
    Schneeweiss, Sebastian
    Najafzadeh, Mehdi
    DIABETES, 2019, 68
  • [26] Cardiovascular effectiveness of empagliflozin compared to DPP4 inhibitors and to GLP1 receptor agonists: Interim analysis from the empagliflozin comparative effectiveness and safety (EMPRISE) study
    Patorno, Elisabetta
    Pawar, Ajinkya
    Franklin, Jessica
    Najafzadeh, Mehdi
    Wexler, Deborah
    Deruaz-Luyet, Anouk
    Brodovicz, Kimberly
    Bessette, Lily
    Schneeweiss, Sebastian
    PHARMACOEPIDEMIOLOGY AND DRUG SAFETY, 2020, 29 : 119 - 119
  • [27] Cardiovascular Effectiveness of Empagliflozin Compared to DPP4 Inhibitors and to GLP1 Receptor Agonists: Interim Analysis From the Empagliflozin Comparative Effectiveness and Safety (EMPRISE) Study
    Patorno, Elisabetta
    Pawar, Ajinkya
    Franklin, Jessica
    Najafzadeh, Mehdi
    Wexler, Deborah
    Deruaz-Luyet, Anouk
    Brodovicz, Kimberly
    Bessette, Lily
    Schneeweiss, Sebastian
    CIRCULATION, 2019, 140
  • [28] COMPARATIVE HEALTHCARE COSTS AND MEDICATION BURDEN IN REAL-WORLD PATIENTS AUGMENTING METFORMIN MONOTHERAPY WITH EMPAGLIFLOZIN FROM THE EMPAGLIFLOZIN COMPARATIVE EFFECTIVENESS AND SAFETY (EMPRISE) STUDY
    Pawar, A.
    Patorno, E.
    Deruaz-Luyet, A.
    Brodovicz, K. G.
    Ustyugova, A.
    Bessette, L. G.
    Ortiz, Santiago A. J.
    Schneeweiss, S.
    Najafzadeh, M.
    VALUE IN HEALTH, 2019, 22 : S161 - S161
  • [29] Empagliflozin selected cardiovascular and safety outcomes in routine care: first results from theempagliflozin comparative effectiveness and safety (EMPRISE) study
    Patorno, Elisabetta
    Pawar, Ajinkya
    Franklin, Jessica M.
    Najafzadeh, Mehdi
    Deruaz-Luyet, Anouk
    Brodovicz, Kimberly G.
    Sambevski, Steven
    Bessette, Lily G.
    Kulldorff, Martin
    Schneeweiss, Sebastian
    PHARMACOEPIDEMIOLOGY AND DRUG SAFETY, 2019, 28 : 419 - 419
  • [30] Empagliflozin cardiovascular and renal effectiveness and safety compared to dipeptidyl peptidase-4 inhibitors across 11 countries in Europe and Asia: Results from the EMPagliflozin compaRative effectIveness and SafEty (EMPRISE) study
    Karasik, Avraham
    Lanzinger, Stefanie
    Tan, Elise Chia -Hui
    Yabe, Daisuke
    Kim, Dae Jung
    Sheu, Wayne H. -H
    Melzer-Cohen, Cheli
    Holl, Reinhard W.
    Ha, Kyoung Hwa
    Khunti, Kamlesh
    Zaccardi, Francesco
    Subramanian, Anuradhaa
    Nirantharakumar, Krishnarajah
    Nystrom, Thomas
    Niskanen, Leo
    Jensen, Majken Linnemann
    Hoti, Fabian
    Klements, Riho
    Deruaz-Luyet, Anouk
    Kyaw, Moe H.
    Koeneman, Lisette
    Vistisen, Dorte
    Carstensen, Bendix
    Halvorsen, Sigrun
    Langslet, Gisle
    Farsani, Soulmaz Fazeli
    Patorno, Elisabetta
    Nunez, Julio
    DIABETES & METABOLISM, 2023, 49 (02)
12345